Tjip S van der Werf

Has grant

professor emeritus

University of Groningen

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Emeritus Tjip S van der Werf is affiliated with the University of Groningen in the Netherlands. His research primarily focuses on the pharmacokinetics of anti-infective drugs, the gut microbiota in gastrointestinal mucositis, and the clinical management of tuberculosis. His recent publications demonstrate a commitment to improving treatment outcomes for patients with invasive infections and drug-sensitive conditions.

Recent Grants

Grant: Close

BuruliVac

Open Date: 2008-01-01

Close Date: 2012-01-01

Grant: Close

Burulico

Open Date: 2005-01-01

Close Date: 2008-01-01

Grant: Close

ZonMW

Open Date: 2000-01-01

Close Date: 2007-01-01

Articles (12)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Roger J M Brüggemann

Radboud University Medical Center

NETHERLANDS

View details

Marieke G. G. Sturkenboom

University Medical Center Groningen

NETHERLANDS

View details

Anne-Grete Märtson

University of Liverpool

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tjip S van der Werf

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (12)

Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study.

Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study

Therapeutic drug monitoring guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised cross-over clinical trial.

Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial

Non-restrictive open vial policy combined with the home visit vaccinations for improving BCG coverage in a high-incidence outreach region: A model-based cost-effectiveness analysis for Indonesia

Isoniazid and rifampicin exposure during treatment in drug-susceptible TB

Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model

Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis

Clinical standards for drug-susceptible TB: putting patients first.

Clinical standards for drug-susceptible TB: putting patients first

Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.

Collaborators (3)

Roger J M Brüggemann

Marieke G. G. Sturkenboom

Anne-Grete Märtson

Make your next move.